Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Colorcon
Dow
McKinsey
AstraZeneca

Last Updated: January 27, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Tasisulam


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Tasisulam?

Tasisulam is an investigational drug.

There have been 12 clinical trials for Tasisulam. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2009.

The most common disease conditions in clinical trials are Neoplasms, Melanoma, and Ovarian Neoplasms. The leading clinical trial sponsors are Eli Lilly and Company and [disabled in preview].

Recent Clinical Trials for Tasisulam
TitleSponsorPhase
A Tasisulam and Midazolam Drug Interaction Study in Cancer PatientsEli Lilly and CompanyPhase 1
A Drug Interaction Study of Tasisulam in Patients With Advanced Cancer or LymphomaEli Lilly and CompanyPhase 1
A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic MelanomaEli Lilly and CompanyPhase 3

See all Tasisulam clinical trials

Clinical Trial Summary for Tasisulam

Top disease conditions for Tasisulam
Top clinical trial sponsors for Tasisulam

See all Tasisulam clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Colorcon
Dow
McKinsey
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.